Konduri N, Aboagye-Nyame F, Mabirizi D, Hoppenworth K, Kibria MG, Doumbia S, Williams L, Mazibuko G.Digital health technologies to support access to medicines and pharmaceutical services in the achievement of sustainable development goals. Digit Health. 2018 May 3;4:2055207618771407. doi: 10.1177/2055207618771407. Read the full article
Archive Journal Article
User experience analysis of an eHealth system for tuberculosis in resource-constrained settings: A nine-country comparison
Konduri N, Bastos LGV, Sawyer K, Reciolino LFA. User experience analysis of an eHealth system for tuberculosis in resource-constrained settings: A nine-country comparison. International Journal of Medical Informatics 102 2017; 118-29. Read the full article
Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected review
Konduri N, Rauscher M. Shio-Chu JW, Malpica-Llanos T. Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected review. Journal of Pharmaceutical Policy and Practice 2017;10:16. Read the full article
User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine
Konduri N, Sawyer K, Nizova N. User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine. European Respiratory Journal Open Research 3;2017: 00002-2017. Read the full article
An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia’s public sector: Findings and therapeutic implications
Kibuule, D., Mubita, M., Naikaku, E., Kalemeera, F., Godman, B. B. and Sagwa, E. (2017), An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia’s public sector: Findings and therapeutic implications. Int J Clin Pract. doi:10.1111/ijcp.12918 Access the full article
Engagement of the private pharmaceutical sector for TB control: rhetoric or reality?
Konduri N, Delmotte E, Rutta E. Engagement of the private pharmaceutical sector for TB control: Rhetoric or reality? Journal: Journal of Pharmaceutical Policy and Practice, 2017, Volume 10, Number 1 Read the full article
Assessment of the World Health Organization’s HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in Namibia
Mutenda N, Bukowski A, Nitschke AM, Nakanyala T, Hamunime N, Mekonen T, Tjituka F, Mazibuko G, Mwinga S, Mabirizi D, Sagwa E, Indongo R, Dean N, Jordan MR, Hong SY. Assessment of the World Health Organization’s HIV drug resistance early warning indicators in main and decentralized outreach antiretroviral therapy sites in Namibia. PLOS One. 2016. … Read more
Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, Babigumira JB, Garrison LP, Stergachis A. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia. Pharmacoepidemiology and Drug Safety. 2016, Vol 25, Issue 9; 1052-1060. Read the full article
Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, Garrison Jr LP, Stergachis A. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in Namibia: A cost-utility analysis. Drug Safety. 2016, Vol. 39, Issue 9; 859-872. Read the full article
Defining pharmaceutical systems strengthening: concepts to enable measurement
Hafner T, Walkowiak H, Lee D, Aboagye-Nyame F. Defining pharmaceutical systems strengthening: Concepts to enable measurement. Health Policy and Planning Advance Access. 2016; 1-13. Read the full article
